OncoMatch/Clinical Trials/NCT07628751
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
Is NCT07628751 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for early hepatocellular carcinoma.
This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour. Investigators hypothesize SABR will result in higher rates of freedom from local progression (FFLP) at 2 years compared to percutaneous thermal ablation ± TACE or transarterial therapies (TACE/TARE).The study will also look at other important outcomes such as progression free survival, overall survival, side effects, quality of life and people's experiences of their treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE 0, BCLC STAGE A (other)
BCLC stage 0 or A
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: treatment for any HCC
Exception: allowed if >2 years prior and for a solitary HCC ≤5 cm in a different segment, treated with curative intent and no evidence of active disease at the site
Prior treatment for any HCC within last 2 years
Cannot have received: abdominal radiation therapy
Exception: only if it would preclude protocol SABR delivery
Prior abdominal radiation therapy that would preclude the delivery of protocol defined SABR to the tumour
Lab requirements
Blood counts
Platelets =50x10^9/L, Haemoglobin =80 g/L, Neutrophils =1.0x10^9/L, INR <1.8 (except if on therapeutic anticoagulation)
Liver function
Child-Pugh score =B7* with no or diuretic-controlled ascites
Child-Pugh score =B7* with no or diuretic-controlled ascites; Platelets =50x10^9/L, Haemoglobin =80 g/L, Neutrophils =1.0x10^9/L, INR <1.8 (except if on therapeutic anticoagulation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07628751 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior treatment for any HCC, abdominal radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage BCLC STAGE 0 or BCLC STAGE A is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages